SALT

Market research proposal

Festal Nº10 role in portfolio evaluation QL

Prepared for



Подготовлено Salt © All rights reserved

From the brief



Project background

"Enzymes" category is one of the several Digestive Health markets – 35 mln packs (-3% vs LY); 5,4 bln rur (+4% vs LY); a homogeneous market without any strong differentiation inside; 80% of the competitors is mono-component pancreatin brands with low-end pricing strategy. TOP players of the category: Kreon (MS 33% in value; 12% in volume), Festal (18% in value; 14% in volume), Mezym (16% in value; 22% in volume) and list of generic Pancreatins (9% in value; 37% in volume). Festal is a traditional medicine (>30 years on the Russian market), #2 in brand awareness, #3 in pharmacists' recommendation (after Kreon and Mezym). Festal has 3 component composition with 2 additional ingredients which gives us superiority vs other mono-component players.

Festal range consists of 4 SKUs with defined strategic role for each one:

- #10 Switching driver/Trial format (launched a year ago) a subject of the research
- #20 Volume driver
- #40 Hero SKU, sales generator
- #100 Value for money format

Key brand source of growth: switch from cheap competitors via <u>new affordable #10 format</u>.

One year after the launch – there is still low level of sales, pharmacists don't recommend this SKU instead of cheap competitors. There is a hypothesis that pharmacists don't see any value in this SKU neither for recommendation nor for profitability.



Research questions and core goal

Core goal:

• To unlock switching trigger from mono-component competitors (Mezym, Pancreatin).

Research questions

- How the pharmacists see their role in DH category, especially related to indigestion symptoms sales, consulters, active switchers etc
- What are their strategies for switching consumers (when, whom and how), what can trigger this switching behavior. What are the best cases they see on the market in switching consumers? What is the role of different packaging on the market? How they define the role of the different sizes, formats?
- How they define Festal portfolio, what is the role of each of the SKU
- Festal #10 current role inside Festal range and in Enzymes category as well
- What are the barriers and triggers for Festal #10 among Pharmacists
- Strengths and weaknesses of Festal #10 format
- Why Festal #100 is preferable to sell by blisters and there is no value to recommend #10 as a finished good
- Consumer portrait of Festal #10 and Festal #20: is there any cannibalization or not
- Is the price difference between Mezym #20 and Festal #10 enough to increase average pharmacy receipt and/or to get more margin
- What kind of arguments we should deliver with MedReps to accelerate #10 sales
- The right messages for Festal differentiating from other enzymes

SALT research methodology

To meet all objectives we recommend the following approach

Desk research

- Collect range of opinions in social networks and forums, check product layout + pricing points in the pharmacies
- Have a quick talks with stakeholders to take their view of the situation



Pharmacists

- Pharmacists role in DH points in patient journey and 'points of sale'
- Triggers/barrier in switching (check role of package and size in particular)
- Perception of Festal portfolio and role for each SKU (strength and weaknesses, check differentiation from Mezym/Pancreatin



3

Consumers

- What is patient journey and what is the role of pharmacist within DH and pancreatin category
- Triggers/barrier in switching (check role of package and size in particular)
- Perception of Festal portfolio and role for each SKU (strength and weaknesses, check differentiation from Mezym/Pancreatin



Analysis

- Key insights and findings related to enzymes category audit – perception, brand image drivers and barriers, brand assets, differentiation points, positioning, communication, target mindset, human truth, etc)
- Role of package size with focus on Festal#10
- Video quotes to support the findings



2 Pharmacists

Methodology & Sample & Geography

12 x 1h in-depth interview in Zoom




| \$ | # of interviews | Chain | Geography | |
|--|-----------------|-------------------|--------------------------------|--|
| | 2 | Planeta Zdoroviya | Moscow + 2 nd city | |
| | 2 | Permpharmacia | Perm | |
| A Solo of B | 2 | Pharmaimplex | Izhevsk + 2 nd city | |
| The state of the s | 2 | Magnit | Moscow + Krasnodar | |
| | 2 | Rigla | Moscow + 2 nd city | |
| | 2 | ASNA | Chelyabinsk + Ufa | |
| | | | | |

Consumers

Methodology & Sample & Geography

4 x 2h focus-groups in Zoom, 6 participants





Age









Budget

| Activity | Cost per 1 | # of units | Total cost |
|---|------------|------------|------------|
| Project management | 60 000 P | 1 | 60 000 ₽ |
| 12 x 1 hour online IDIs with pharmacists | | | |
| Field project management | 30 000 ₽ | 1 | 30 000 ₽ |
| Guidelines development | 40 000 P | 1 | 40 000 ₽ |
| Recruitment and fieldwork | 8 000 ₽ | 12 | 96 000 ₽ |
| Moderation | 10 000 ₽ | 12 | 120 000 ₽ |
| Technical support, including platform (Zoom) | 3 000 ₽ | 12 | 36 000 ₽ |
| | | | |
| 4 x 2 hours online focus-groups with consumers (6 participants) | | | |
| Field project management | 45 000 ₽ | 1 | 45 000 ₽ |
| Guidelines development | 20 000 ₽ | 1 | 20 000 ₽ |
| Recruitment and fieldwork | 43 400 ₽ | 4 | 96 000 ₽ |
| Moderation | 14 000 ₽ | 4 | 56 000 ₽ |
| Technical support, including platform (Zoom) | 3 000 ₽ | 4 | 12 000 ₽ |
| Analysis and full report | 120 000 ₽ | 1 | 120 000 ₽ |
| | | | |
| GRAND TOTAL | | | 731 000 P |



We believe that anything is possible.

Our task is to choose the right direction

www.salt-research.com

+7 495 987 21 61 / Whatsapp/Telegram - +79031682480

In case of questions, please, write to Maxim Drozd - md@salt-research.com